pembrolizumab,capmatinib
incyte,novartis,merck
['sclc', 'capmatinib', 'lung', 'pembro', 'nsclc']
in a met-unselected population of pd-l1 positive non small cell lung cancer, the addition of capmatinib to pembrolizumab did not lead to more responses but increased toxicity. #nsclc #asco22 | 
Home of the journal ONCOLOGY®, CancerNetwork® offers different perspectives on oncology/hematology through review articles, news, podcasts, blogs, and more.